NCT03266445 is a Phase 4 clinical trial of buprenorphine/naloxone in Opioid-use Disorder, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT03266445?

NCT03266445 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT03266445?

Interventions in NCT03266445: buprenorphine/naloxone.

What condition does NCT03266445 study?

NCT03266445 studies Opioid-use Disorder, Pain, Acute, Surgery.

Is NCT03266445 still recruiting?

NCT03266445 is currently status unknown. Last updated 9 October 2018.

Last reviewed 2018-10-09 · How we verify

NCT03266445

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use

Status unknown Phase 4 Last updated 9 October 2018

What this trial tests

Phase 4 trial testing buprenorphine/naloxone in Opioid-use Disorder in 76 participants. Status unknown.

Timeline

5 October 2018

Primary endpoint
31 December 2021

26 February 2022

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	5 October 2018
Primary completion	31 December 2021
Estimated completion	26 February 2022

Drugs / interventions tested

buprenorphine/naloxone

Conditions studied

Opioid-use Disorder — all drugs for Opioid-use Disorder →
Pain, Acute — all drugs for Pain, Acute →
Surgery — all drugs for Surgery →

Sponsor

Massachusetts General Hospital

Who can join

Adults 18 to 65, any sex, with Opioid-use Disorder or Pain, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine the effect of continuation of buprenorphine/naloxone in patients with history of Opioid Use Disorder (OUD) scheduled for surgery compared to reduced dose buprenorphine/naloxone prior to surgery on pain scores, opioid consumption, depressive symptoms and severity of substance use dependence- including record of problematic use of any non-prescribed opioids, alcohol and illicit narcotics.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of buprenorphine/naloxone

Trials testing the same drug.

NCT05944952 — Low-dose Versus a High-dose Sublingual Buprenorphine Induction · Phase 4 · active not recruiting
NCT05644587 — Novel Induction to Buprenorphine/Naloxone · Phase 4 · terminated
NCT05062577 — A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With · Phase 2 · withdrawn
NCT04447287 — A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics · Phase 1 · completed
NCT03908437 — Rapid Initiation of Drug Treatment Engagement · Phase 4 · completed

Other recruiting trials for Opioid-use Disorder

Currently open trials in the same condition.

NCT04783558 — Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk · NA · active not recruiting
NCT05011266 — Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder · Phase 2, PHASE3 · recruiting
NCT05039554 — Randomized Trial of ACT and a Care Management App in Primary Care-based Buprenorphine Treatment · NA · recruiting
NCT05033028 — Smartphones for Opiate Addiction Recovery · Phase 3 · recruiting
NCT04738825 — Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With Pr · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03266445 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 9 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03266445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing